In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Cerebral Perfusion-based Single-photon Emission Computed Tomography (SPECT) Staging Using NeuroGam® in Patients With Moyamoya Disease

    Final Number:

    Jai - Hyuck Han MD; Young Seok Park MD PhD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2016 Annual Meeting

    Introduction: Cerebral angiography (CA) is the gold standard for moyamoya disease (MMD) staging and diagnosis, but CA findings are not well-correlated with clinical symptoms. The purpose of this study was to establish novel cerebral perfusion-based staging for MMD that is well-correlated with clinical symptoms.

    Methods: From 2010 to 2015, regional cerebrovascular reserve (rCVR) was examined by single-photon emission computed tomography (SPECT) using NeuroGam® (Segamicorp, Houston, TX, USA) in 30 patients (17 women, 13 men; 60 hemispheres; mean 42.0 years old [range: 5-60 years old]) with MMD, which was diagnosed by CA and magnetic resonance angiography (MRA). Brain CT or brain magnetic resonance imaging (MRI) was used to evaluate neurological conditions such as transient ischemic attack (TIA), cerebral hemorrhage, and cerebral infarction. A novel staging system for MMD was developed by combining findings from CA, MRI, and SPECT with NeuroGam®.

    Results: Our novel staging system was strongly associated with clinical symptoms. Of the 22 hemispheres classified as stage 1, 3 (13.6 %) exhibited neurological symptoms, whereas 66.7% (16 of 24) of the hemispheres classified as stage 2 and 85.7% (12 of 14) of the hemispheres classified as stage 3 exhibited neurologic symptoms. These findings indicate that cerebral perfusion-based staging is predictive of MMD clinical symptoms.

    Conclusions: Perfusion-based SPECT staging correlates well with clinical symptoms and may be a reliable alternative to the Suzuki staging by CA.

    Patient Care: The use of NeuroGam® to analyze the CVR image is particularly valuable in the visualization of an impaired functional area. In this study, a novel staging system for MMD was proposed using NeuroGam® with SPECT in combination with CA and MRI. This staging system also is predictive of the clinical symptoms associated with MMD. Thus, this novel staging system provides a better method by which to diagnose and stage MMD both for preoperative clinical assessments and postoperative follow-up. This perfusion-based SPECT staging should be considered a reliable alternative to conventional staging methods.

    Learning Objectives: This perfusion-based SPECT staging should be considered a reliable alternative to conventional staging methods

    References: [1] Takeuchi S, Kobayashi K, Tsuchida T, Imamura H, Tanaka R, Ito J (1982) Computed tomography in moyamoya disease. Journal of computer assisted tomography 6: 24-32 [2] Takahashi M, Miyauchi T, Kowada M (1980) Computed tomography of Moyamoya disease: demonstration of occluded arteries and collateral vessels as important diagnostic signs. Radiology 134: 671-676 [3] Suzuki J, Takaku A (1969) Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Archives of neurology 20: 288-299 [4] Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. The New England journal of medicine 360: 1226-1237 [5] Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. The Lancet Neurology 7: 1056-1066 [6] Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clinical neurology and neurosurgery 99 Suppl 2: S238-240 [7] Fukui M (1997) Current state of study on moyamoya disease in Japan. Surgical neurology 47: 138-143 [8] Lee M, Zaharchuk G, Guzman R, Achrol A, Bell-Stephens T, Steinberg GK (2009) Quantitative hemodynamic studies in moyamoya disease: a review. Neurosurgical focus 26: E5 [9] Suzuki J, Kodama N (1983) Moyamoya disease--a review. Stroke; a journal of cerebral circulation 14: 104-109 [10] Saito N, Nakagawara J, Nakamura H, Teramoto A (2004) Assessment of cerebral hemodynamics in childhood moyamoya disease using a quantitative and a semiquantitative IMP-SPECT study. Annals of nuclear medicine 18: 323-331 [11] So Y, Lee HY, Kim SK, Lee JS, Wang KC, Cho BK, Kang E, Lee DS (2005) Prediction of the clinical outcome of pediatric moyamoya disease with postoperative basal/acetazolamide stress brain perfusion SPECT after revascularization surgery. Stroke; a journal of cerebral circulation 36: 1485-1489 [12] Yamada I, Suzuki S, Matsushima Y (1995) Moyamoya disease: comparison of assessment with MR angiography and MR imaging versus conventional angiography. Radiology 196: 211-218 [13] Houkin K, Nakayama N, Kuroda S, Nonaka T, Shonai T, Yoshimoto T (2005) Novel magnetic resonance angiography stage grading for moyamoya disease. Cerebrovascular diseases 20: 347-354 [14] Suzuki J, Kodama N (1971) Cerebrovascular "Moyamoya" disease. 2. Collateral routes to forebrain via ethmoid sinus and superior nasal meatus. Angiology 22: 223-236 [15] Song YS, Oh SW, Kim YK, Kim SK, Wang KC, Lee DS (2012) Hemodynamic improvement of anterior cerebral artery territory perfusion induced by bifrontal encephalo(periosteal) synangiosis in pediatric patients with moyamoya disease: a study with brain perfusion SPECT. Annals of nuclear medicine 26: 47-57 [16] Houkin K, Aoki T, Takahashi A, Abe H (1994) Diagnosis of moyamoya disease with magnetic resonance angiography. Stroke; a journal of cerebral circulation 25: 2159-2164 [17] Kaufmann TJ, Huston J, 3rd, Mandrekar JN, Schleck CD, Thielen KR, Kallmes DF (2007) Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. Radiology 243: 812-819 [18] Willinsky RA, Taylor SM, TerBrugge K, Farb RI, Tomlinson G, Montanera W (2003) Neurologic complications of cerebral angiography: prospective analysis of 2,899 procedures and review of the literature. Radiology 227: 522-528 [19] Honda M, Ezaki Y, Kitagawa N, Tsutsumi K, Ogawa Y, Nagata I (2006) Quantification of the regional cerebral blood flow and vascular reserve in moyamoya disease using split-dose iodoamphetamine I 123 single-photon emission computed tomography. Surgical neurology 66: 155-159; discussion 159 [20] Kuhn FP, Warnock G, Schweingruber T, Sommerauer M, Buck A, Khan N (2015) Quantitative H2[(15)O]-PET in Pediatric Moyamoya Disease: Evaluating Perfusion before and after Cerebral Revascularization. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 24: 965-971 [21] Togao O, Mihara F, Yoshiura T, Tanaka A, Noguchi T, Kuwabara Y, Kaneko K, Matsushima T, Honda H (2006) Cerebral hemodynamics in Moyamoya disease: correlation between perfusion-weighted MR imaging and cerebral angiography. AJNR American journal of neuroradiology 27: 391-397 [22] Kuroda S, Houkin K, Kamiyama H, Mitsumori K, Iwasaki Y, Abe H (2001) Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it? Stroke; a journal of cerebral circulation 32: 2110-2116 [23] Horowitz M, Yonas H, Albright AL (1995) Evaluation of cerebral blood flow and hemodynamic reserve in symptomatic moyamoya disease using stable Xenon-CT blood flow. Surgical neurology 44: 251-261; discussion 262 [24] McAuley DJ, Poskitt K, Steinbok P (2004) Predicting stroke risk in pediatric moyamoya disease with xenon-enhanced computed tomography. Neurosurgery 55: 327-332; discussion 332-323 [25] Webster MW, Makaroun MS, Steed DL, Smith HA, Johnson DW, Yonas H (1995) Compromised cerebral blood flow reactivity is a predictor of stroke in patients with symptomatic carotid artery occlusive disease. Journal of vascular surgery 21: 338-344; discussion 344-335 [26] Tanaka Y, Nariai T, Nagaoka T, Akimoto H, Ishiwata K, Ishii K, Matsushima Y, Ohno K (2006) Quantitative evaluation of cerebral hemodynamics in patients with moyamoya disease by dynamic susceptibility contrast magnetic resonance imaging--comparison with positron emission tomography. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 26: 291-300 [27] Calamante F, Ganesan V, Kirkham FJ, Jan W, Chong WK, Gadian DG, Connelly A (2001) MR perfusion imaging in Moyamoya Syndrome: potential implications for clinical evaluation of occlusive cerebrovascular disease. Stroke; a journal of cerebral circulation 32: 2810-2816 [28] Kuwabara Y, Ichiya Y, Sasaki M, Yoshida T, Masuda K, Matsushima T, Fukui M (1997) Response to hypercapnia in moyamoya disease. Cerebrovascular response to hypercapnia in pediatric and adult patients with moyamoya disease. Stroke; a journal of cerebral circulation 28: 701-707 [29] Ikezaki K, Matsushima T, Kuwabara Y, Suzuki SO, Nomura T, Fukui M (1994) Cerebral circulation and oxygen metabolism in childhood moyamoya disease: a perioperative positron emission tomography study. Journal of neurosurgery 81: 843-850 [30] Kanno I, Uemura K, Higano S, Murakami M, Iida H, Miura S, Shishido F, Inugami A, Sayama I (1988) Oxygen extraction fraction at maximally vasodilated tissue in the ischemic brain estimated from the regional CO2 responsiveness measured by positron emission tomography. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 8: 227-235 [31] Nariai T, Matsushima Y, Imae S, Tanaka Y, Ishii K, Senda M, Ohno K (2005) Severe haemodynamic stress in selected subtypes of patients with moyamoya disease: a positron emission tomography study. Journal of neurology, neurosurgery, and psychiatry 76: 663-669 [32] Nariai T, Senda M, Ishii K, Wakabayashi S, Yokota T, Toyama H, Matsushima Y, Hirakawa K (1998) Posthyperventilatory steal response in chronic cerebral hemodynamic stress: a positron emission tomography study. Stroke; a journal of cerebral circulation 29: 1281-1292 [33] Grubb RL, Jr., Derdeyn CP, Fritsch SM, Carpenter DA, Yundt KD, Videen TO, Spitznagel EL, Powers WJ (1998) Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. Jama 280: 1055-1060 [34] Marushima A, Tsurushima H, Suzuki K, Nakai Y, Nemoto H, Matsumura A (2011) Time-course analysis of brain perfusion single photon emission computed tomography using a three-dimensional stereotactic region-of-interest template in patients with moyamoya disease. World neurosurgery 76: 304-310 [35] Hoshi H, Ohnishi T, Jinnouchi S, Futami S, Nagamachi S, Kodama T, Watanabe K, Ueda T, Wakisaka S (1994) Cerebral blood flow study in patients with moyamoya disease evaluated by IMP SPECT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 35: 44-50 [36] Lee SK, Kim DI, Jeong EK, Kim SY, Kim SH, In YK, Kim DS, Choi JU (2003) Postoperative evaluation of moyamoya disease with perfusion-weighted MR imaging: initial experience. AJNR American journal of neuroradiology 24: 741-747 [37] Nagasawa N, Yamakado K, Yamada T, Nakanishi S, Ito M, Suzawa N, Kitano T, Takeda K (2009) Three-dimensional stereotactic ROI template for measuring regional cerebral blood flow in 99mTc-ECD SPECT: comparison with the manual tracing method. Nuclear medicine communications 30: 155-159 [38] Takeuchi R, Matsuda H, Yonekura Y, Sakahara H, Konishi J (1997) Noninvasive quantitative measurements of regional cerebral blood flow using technetium-99m-L,L-ECD SPECT activated with acetazolamide: quantification analysis by equal-volume-split 99mTc-ECD consecutive SPECT method. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 17: 1020-1032 [39] Touho H, Karasawa J, Ohnishi H (1996) Preoperative and postoperative evaluation of cerebral perfusion and vasodilatory capacity with 99mTc-HMPAO SPECT and acetazolamide in childhood Moyamoya disease. Stroke; a journal of cerebral circulation 27: 282-289 [40] Hill TC, Holman BL, Lovett R, O'Leary DH, Front D, Magistretti P, Zimmerman RE, Moore S, Clouse ME, Wu JL, Lin TH, Baldwin RM (1982) Initial experience with SPECT (single-photon computerized tomography) of the brain using N-isopropyl I-123 p-iodoamphetamine: concise communication. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 23: 191-195 [41] Kuhl DE, Barrio JR, Huang SC, Selin C, Ackermann RF, Lear JL, Wu JL, Lin TH, Phelps ME (1982) Quantifying local cerebral blood flow by N-isopropyl-p-[123I]iodoamphetamine (IMP) tomography. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 23: 196-203 [42] Lee RG, Hill TC, Holman BL, Royal HD, O'Leary DH, Clouse ME (1984) Predictive value of perfusion defect size using N-isopropyl-(I-123)-p-iodoamphetamine emission tomography in acute stroke. Journal of neurosurgery 61: 449-452 [43] Magistretti P, Uren R, Blume H, Schomer D, Royal H (1982) Delineation of epileptic focus by single photon emission tomography. European journal of nuclear medicine 7: 484-485 [44] Holman BL, Hill TC, Polak JF, Lee RG, Royal HD, O'Leary DH (1984) Cerebral perfusion imaging with iodine 123-labeled amines. Archives of neurology 41: 1060-1063 [45] Defer G, Moretti JL, Cesaro P, Sergent A, Raynaud C, Degos JD (1987) Early and delayed SPECT using N-isopropyl p-iodoamphetamine iodine 123 in cerebral ischemia. A prognostic index for clinical recovery. Archives of neurology 44: 715-718 [46] Heyn C, Poublanc J, Crawley A, Mandell D, Han JS, Tymianski M, terBrugge K, Fisher JA, Mikulis DJ (2010) Quantification of cerebrovascular reactivity by blood oxygen level-dependent MR imaging and correlation with conventional angiography in patients with Moyamoya disease. AJNR American journal of neuroradiology 31: 862-867

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy